{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:08:45Z","timestamp":1789049325437,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,10]]},"DOI":"10.7759\/cureus.116053","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:20:28Z","timestamp":1789046428000},"source":"Crossref","is-referenced-by-count":0,"title":["Trimodal Therapy for Primary Squamous Cell Carcinoma of the Vagina: A Case Report"],"prefix":"10.7759","author":[{"given":"Jake","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R","family":"Eanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.13867","article-title":"Cancer of the vagina: 2021 update","volume":"155","author":"Adams TS","year":"2021","unstructured":"Adams TS, Rogers LJ, Cuello MA. Cancer of the vagina: 2021 update. Int J Gynaecol Obstet. 2021, 155:19-27. 10.1002\/ijgo.13867","journal-title":"Int J Gynaecol Obstet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23757","article-title":"Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States","volume":"113","author":"Wu X","year":"2008","unstructured":"Wu X, Matanoski G, Chen VW, Saraiya M, Coughlin SS, King JB, Tao XG. Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer. 2008, 113:2873-82. 10.1002\/cncr.23757","journal-title":"Cancer"},{"key":"ref3","unstructured":"Recent trends in SEER age-adjusted incidence rates, 2000-2023. (2025). https.\/\/seer.cancer.gov\/statistics-network\/explorer\/.."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33055","article-title":"Geographic and temporal variations in the incidence of vulvar and vaginal cancers","volume":"147","author":"Bray F","year":"2020","unstructured":"Bray F, Laversanne M, Weiderpass E, Arbyn M. Geographic and temporal variations in the incidence of vulvar and vaginal cancers. Int J Cancer. 2020, 147:2764-71. 10.1002\/ijc.33055","journal-title":"Int J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30855-1","article-title":"Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer","volume":"21","author":"Westerveld H","year":"2020","unstructured":"Westerveld H, Nesvacil N, Fokdal L, et al.. Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer. Lancet Oncol. 2020, 21:157-67. 10.1016\/S1470-2045(19)30855-1","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacr.2021.08.011","article-title":"ACR appropriateness criteria staging and follow-up of primary vaginal cancer","volume":"18","author":"Kilcoyne A","year":"2021","unstructured":"Kilcoyne A, Gottumukkala RV, Kang SK, et al.. ACR appropriateness criteria staging and follow-up of primary vaginal cancer. J Am Coll Radiol. 2021, 18:442-55. 10.1016\/j.jacr.2021.08.011","journal-title":"J Am Coll Radiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35105","article-title":"Human papillomavirus prevalence, genotype distribution, and prognostic factors of vaginal cancer","volume":"155","author":"Tung H","year":"2024","unstructured":"Tung H, Wang Y, Lin C, et al.. Human papillomavirus prevalence, genotype distribution, and prognostic factors of vaginal cancer. Int J Cancer. 2024, 155:1996-2008. 10.1002\/ijc.35105","journal-title":"Int J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.883805","article-title":"A comprehensive discussion in vaginal cancer based on mechanisms, treatments, risk factors and prevention","volume":"12","author":"Baral SK","year":"2022","unstructured":"Baral SK, Biswas P, Kaium MA, et al.. A comprehensive discussion in vaginal cancer based on mechanisms, treatments, risk factors and prevention. Front Oncol. 2022, 12:10.3389\/fonc.2022.883805","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32078","article-title":"Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina","volume":"145","author":"Bertoli HK","year":"2019","unstructured":"Bertoli HK, Rasmussen CL, Sand FL, Albieri V, Norrild B, Verdoodt F, Kjaer SK. Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina. Int J Cancer. 2019, 145:78-86. 10.1002\/ijc.32078","journal-title":"Int J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.04.004","article-title":"Vaginal cancer","volume":"81","author":"Di Donato V","year":"2012","unstructured":"Di Donato V, Bellati F, Fischetti M, Plotti F, Perniola G, Panici PB. Vaginal cancer. Crit Rev Oncol Hematol. 2012, 81:286-95. 10.1016\/j.critrevonc.2011.04.004","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-002517","article-title":"Updates in the treatment of vaginal cancer","volume":"32","author":"Jhingran A","year":"2022","unstructured":"Jhingran A. Updates in the treatment of vaginal cancer. Int J Gynecol Cancer. 2022, 32:344-51. 10.1136\/ijgc-2021-002517","journal-title":"Int J Gynecol Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6502","article-title":"A population-based study of squamous cell vaginal cancer: HPV and cofactors","volume":"84","author":"Daling JR","year":"2002","unstructured":"Daling JR, Madeleine MM, Schwartz SM, et al.. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002, 84:263-70. 10.1006\/gyno.2001.6502","journal-title":"Gynecol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.08.036","article-title":"Management and outcomes of primary vaginal cancer","volume":"159","author":"Yang J","year":"2020","unstructured":"Yang J, Delara R, Magrina J, et al.. Management and outcomes of primary vaginal cancer. Gynecol Oncol. 2020, 159:456-63. 10.1016\/j.ygyno.2020.08.036","journal-title":"Gynecol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.08.012","article-title":"Primary squamous cell carcinoma of the vagina: prognostic factors, treatment patterns, and outcomes","volume":"131","author":"Hiniker SM","year":"2013","unstructured":"Hiniker SM, Roux A, Murphy JD, Harris JP, Tran PT, Kapp DS, Kidd EA. Primary squamous cell carcinoma of the vagina: prognostic factors, treatment patterns, and outcomes. Gynecol Oncol. 2013, 131:380-5. 10.1016\/j.ygyno.2013.08.012","journal-title":"Gynecol Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2014.09.002","article-title":"Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors","volume":"93","author":"Gadducci A","year":"2015","unstructured":"Gadducci A, Fabrini MG, Lanfredini N, Sergiampietri C. Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors. Crit Rev Oncol Hematol. 2015, 93:211-24. 10.1016\/j.critrevonc.2014.09.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-1825","article-title":"Survival and prognostic factors in primary vaginal cancer: an analysis of 2004-2014 SEER data","volume":"9","author":"Huang J","year":"2020","unstructured":"Huang J, Cai M, Zhu Z. Survival and prognostic factors in primary vaginal cancer: an analysis of 2004-2014 SEER data. Transl Cancer Res. 2020, 9:7091-102. 10.21037\/tcr-20-1825","journal-title":"Transl Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.0011","article-title":"Vaginal cancer, version 2.2026, NCCN Clinical Practice Guidelines in Oncology","volume":"24","author":"Abu-Rustum NR","year":"2026","unstructured":"Abu-Rustum NR, Campos SM, Amarnath S, et al.. Vaginal cancer, version 2.2026, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2026, 24:101-26. 10.6004\/jnccn.2026.0011","journal-title":"J Natl Compr Canc Netw"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004956","article-title":"Trimodal definitive invasive vaginal carcinoma treatment (TRIDENT protocol): how a standardized approach may change prognostic outcomes","volume":"34","author":"Lancellotta V","year":"2024","unstructured":"Lancellotta V, Macchia G, Garganese G, et al.. Trimodal definitive invasive vaginal carcinoma treatment (TRIDENT protocol): how a standardized approach may change prognostic outcomes. Int J Gynecol Cancer. 2024, 34:197-202. 10.1136\/ijgc-2023-004956","journal-title":"Int J Gynecol Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/442687-trimodal-therapy-for-primary-squamous-cell-carcinoma-of-the-vagina-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:20:29Z","timestamp":1789046429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/442687-trimodal-therapy-for-primary-squamous-cell-carcinoma-of-the-vagina-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.116053","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}